<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4846067</article-id><article-id pub-id-type="doi">10.2147/OTT.S91796</article-id><article-id pub-id-type="publisher-id">ott-9-2317</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Weiqi</given-names></name><xref ref-type="aff" rid="af1-ott-9-2317"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Caihui</given-names></name><xref ref-type="aff" rid="af1-ott-9-2317"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ruifeng</given-names></name><xref ref-type="aff" rid="af1-ott-9-2317"/><xref ref-type="corresp" rid="c1-ott-9-2317"/></contrib></contrib-group><aff id="af1-ott-9-2317">Department of Radiation Oncology, Guangqian Hospital, Quanzhou, Fujian, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-ott-9-2317">Correspondence: Ruifeng Li, Department of Radiation Oncology, Guangqian Hospital, No 109, West Guangqian Road, Meishan Town, Quanzhou 362321, Fujian, People&#x02019;s Republic of China, Tel +86 595 8657 2018, Fax +86 595 8658 5153, Email <email>ah_kay_aqi@msn.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>4</month><year>2016</year></pub-date><volume>9</volume><fpage>2317</fpage><lpage>2327</lpage><permissions><copyright-statement>&#x000a9; 2016 Zheng et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Integrin expression has been identified as a prognostic factor in non-small-cell lung cancer (NSCLC). This study was aimed at determining the predictive ability of integrins and associated genes identified within the molecular network.</p></sec><sec><title>Patients and methods</title><p>A total of 959 patients with NSCLC from The Cancer Genome Atlas cohorts were enrolled in this study. The expression profile of integrins and related genes were obtained from The Cancer Genome Atlas RNAseq database. Clinicopathological characteristics, including age, sex, smoking history, stage, histological subtype, neoadjuvant therapy, radiation therapy, and overall survival (OS), were collected. Cox proportional hazards regression models as well as Kaplan&#x02013;Meier curves were used to assess the relative factors.</p></sec><sec><title>Results</title><p>In the univariate Cox regression model, <italic>ITGA1, ITGA5, ITGA6, ITGB1, ITGB4</italic>, and <italic>ITGA11</italic> were predictive of NSCLC prognosis. After adjusting for clinical factors, ITGA5 (odds ratio =1.17, 95% confidence interval: 1.05&#x02013;1.31) and <italic>ITGB1</italic> (odds ratio =1.31, 95% confidence interval: 1.10&#x02013;1.55) remained statistically significant. In the gene cluster network analysis, <italic>PLAUR, ILK, SPP1, PXN</italic>, and <italic>CD9</italic>, all associated with <italic>ITGA5</italic> and <italic>ITGB1</italic>, were identified as independent predictive factors of OS in NSCLC.</p></sec><sec><title>Conclusion</title><p>A set of genes was identified as independent prognostic factors of OS in NSCLC through gene cluster analysis. This method may act as a tool to reveal more prognostic-associated genes in NSCLC.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>integrin</kwd><kwd>prognosis</kwd><kwd>non-small-cell lung cancer</kwd><kwd><italic>ITGA5</italic></kwd><kwd><italic>ITGB1</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common malignancies and the most common cause of cancer-related mortality worldwide.<xref rid="b1-ott-9-2317" ref-type="bibr">1</xref> The prognosis of patients with NSCLC, especially in an advanced stage, is generally poor where the 5-year survival rate is &#x0003c;10%.<xref rid="b2-ott-9-2317" ref-type="bibr">2</xref></p><p>Integrins are heterodimeric cell-surface adhesion receptors generally consisting of noncovalently linked alpha and beta subunits. A total of 18 alpha and eight beta subunits with different functions are currently known.<xref rid="b3-ott-9-2317" ref-type="bibr">3</xref> Integrin family members participate in a variety of processes influencing the cell&#x02019;s biological behavior, including cell adhesion, recognition, immune response, metastasis of tumor cells as well as embryogenesis, hemostasis, and tissue repair.<xref rid="b4-ott-9-2317" ref-type="bibr">4</xref> Alterations in integrin expression levels can influence cancer cell adhesion, polarity, and extracellular matrix assembly, which may result in tumor metastasis.<xref rid="b5-ott-9-2317" ref-type="bibr">5</xref> Integrins can also interact with tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR) and vascular EGFR (VEGFR), to promote cancer cell proliferation, survival, and differentiation.<xref rid="b6-ott-9-2317" ref-type="bibr">6</xref> EGFR mutations frequentlyoccur in patients with lung cancer, and these patients have been found to benefit from tyrosine kinase inhibitor-targeted therapy rather than first-line chemotherapy.<xref rid="b7-ott-9-2317" ref-type="bibr">7</xref></p><p>There was a report that discussed the integrin profile and prognosis in NSCLC;<xref rid="b8-ott-9-2317" ref-type="bibr">8</xref> however, external validation and interactions of integrins within the network of integrins were not determined. The Cancer Genome Atlas (TCGA) database has been developed in recent years using a large amount of NSCLC RNAseq data as well as detailed clinical data, and this has made bioinformatic data mining convenient and reliable.<xref rid="b9-ott-9-2317" ref-type="bibr">9</xref> This study was aimed at determining the prognostic ability of integrins and associated genes identified through the molecular network using TCGA database analysis in NSCLC.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="subjects"><title>Patients</title><p>Expression data of integrins and their associated genes and relative clinical data of patients with NSCLC were available in TCGA database provided on the website of the Cancer Genomics Browser of the University of California Santa Cruz (<ext-link ext-link-type="uri" xlink:href="https://genome-cancer.ucsc.edu/">https://genome-cancer.ucsc.edu/</ext-link>). Thirty members of the integrin family were included in our study (<xref ref-type="supplementary-material" rid="SD1-ott-9-2317">Table S1</xref>). There were 1,092 patients with NSCLC enrolled in TCGA database (updated on February 24, 2015) according to the parameters defined in a previous study.<xref rid="b10-ott-9-2317" ref-type="bibr">10</xref> Patients without fully characterized tumors, deficient overall survival (OS) data, or incomplete RNAseq information were excluded from the study. Clinicopathological characteristics, including age, sex, histology, TNM stage, American Joint Committee on Cancer stage, smoking status, and history of neoadjuvant and radiation therapy, were collected. Information on integrin family genes was also obtained from TCGA RNAseq database. Networks of integrin genes, which were independent prognostic predictors of NSCLC, were obtained from the cBioPortal website (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/public-portal/cgds_r.jsp">http://www.cbioportal.org/public-portal/cgds_r.jsp</ext-link>). Network filters were set as &#x0201c;in the same complex&#x0201d; or &#x0201c;interacted with each other&#x0201d;, and threshold was set as &#x0003e;12% changes.</p><p>This study is based on publicly available data from TCGA database and did not involve interaction with human subjects or the use of personal identifying information. The study was approved by the Institutional Review Board of Guangqian Hospital, Quanzhou, Fujian, People&#x02019;s Republic of China.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>OS was defined as time from the date of diagnosis to the date of death or the last follow-up. Patients without an event of death were recorded as censored at the time of last follow-up. The R project (3.1.3) was used to perform statistical analysis. Survival curves were constructed using the Kaplan&#x02013;Meier method, with log-rank tests used to assess differences between groups. Univariate and multivariate Cox proportional hazards models were used to analyze the relationship between integrin network expression and OS of patients with NSCLC in TCGA cohort. A two-sided <italic>P</italic>-value &#x0003c;0.05 was considered statistically significant. Odds ratios with 95% confidence intervals (CIs) were calculated.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical factors in TCGA cohorts</title><p>A total of 959 patients with NSCLC, including 576 men and 383 women, from TCGA cohort were enrolled in the current study. The median age of the cohort was 67. There were 485 patients diagnosed with adenocarcinoma and 474 patients diagnosed with squamous cell carcinoma (SCC). Detailed clinicopathological data are shown in <xref ref-type="table" rid="t1-ott-9-2317">Table 1</xref>. The median OS in this cohort was 16.7 months.</p></sec><sec><title>ITGA5 and ITGB1 expressions were independent prognostic factors for OS in TCGA cohort</title><p>In univariate Cox regression analysis, <italic>ITGA1, ITGA5, ITGA6, ITGB1, ITGB4</italic>, and <italic>ITGA11</italic> were significantly associated with OS in patients with NSCLC (all <italic>P</italic>&#x0003c;0.05, <xref ref-type="table" rid="t2-ott-9-2317">Table 2</xref>). In multivariate models, after adjusting for age, sex, stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history, <italic>ITGA5</italic> (HR =1.17, 95% CI: 1.05&#x02013;1.31) and <italic>ITGB1</italic> (HR =1.31, 95% CI: 1.10&#x02013;1.55) were independent predictors of prognosis (all <italic>P</italic>&#x0003c;0.01, <xref ref-type="table" rid="t2-ott-9-2317">Table 2</xref>).</p><p>We then divided TCGA cohort according to the histological subtype. In TCGA NSCLC cohort, large-cell carcinoma data were not available; therefore, we analyzed only two subgroups of adenocarcinoma and SCC. In 485 patients with adenocarcinoma, <italic>ITGA5</italic> (HR =1.316, 95% CI: 1.135&#x02013;1.525) and <italic>ITGB1</italic> (HR =1.788, 95% CI: 1.399&#x02013;2.286) were associated with OS in univariate analysis. However, in multivariate analysis, <italic>ITGA6</italic> (HR =1.208, 95% CI: 1.014&#x02013;1.439) was found to be the unique, independent prognostic factor. Also, <italic>ITGA5</italic> (HR =1.142, 95% CI: 1.005&#x02013;1.299) and <italic>ITGB1</italic> (HR =1.231, 95% CI: 1.006&#x02013;1.507) were prognostic factors of 474 patients with SCC with univariate analysis. After adjusting for clinical factors and other integrin family members, <italic>ITGA3</italic> (HR =1.182, 95% CI: 1.002&#x02013;1.394) was the only prognostic factor (<xref ref-type="table" rid="t3-ott-9-2317">Table 3</xref>).</p><p>Further studies of integrin and lymph node metastasis and distant metastasis were conducted with Spearman&#x02019;s correlation analysis. <italic>ITGA3, ITGB5, ITGB6</italic>, and <italic>ITGB8</italic> were associated with lymph node staging of SCC. <italic>ITGB1</italic> was the only factor correlated with distant metastasis in SCC. The pattern was different in adenocarcinoma. <italic>ITGA5, ITGA7, ITGA9, ITGAD, ITGAL</italic>, and <italic>ITGAV</italic> were associated with N stage, and <italic>ITGA3, ITGB1BP3, ITGB5</italic>, and <italic>ITGBL1</italic> were correlated with M stage (<xref ref-type="supplementary-material" rid="SD2-ott-9-2317">Table S2</xref>).</p><p>Expression levels of <italic>ITGA5</italic> and <italic>ITGB1</italic> in TCGA cohort showed nearly normal distribution (data not shown); therefore, we divided the cohort into low and high expressers according to the median expression levels of <italic>ITGA5</italic> and <italic>ITGB1</italic>. Kaplan&#x02013;Meier plots demonstrated that high expressers of <italic>ITGA5</italic> or <italic>ITGB1</italic> were associated with poor OS (all <italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f1-ott-9-2317">Figure 1A and B</xref>). Moreover, in subgroup analysis, ITGA5 and ITGB1 were associated with poor prognosis of adenocarcinoma as well as SCC (all <italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="f2-ott-9-2317">Figure 2A&#x02013;D</xref>).</p></sec><sec sec-type="methods"><title>ITGA5 and ITGB1 gene cluster analysis and its association with prognosis</title><p>Although difference in integrin expression pattern existed between SCC and adenocarcinoma of lung cancer, <italic>ITGA5</italic> and <italic>ITGB1</italic> were more important genes because a selective inhibitor cilengitide has been developed.<xref rid="b11-ott-9-2317" ref-type="bibr">11</xref> Therefore, the gene networks of <italic>ITGA5</italic> and <italic>ITGB1</italic> were studied. Three situations were selected for building the interaction network of <italic>ITGA5</italic> and <italic>ITGB1</italic> (<xref ref-type="fig" rid="f3-ott-9-2317">Figure 3</xref>). They were stated as &#x0201c;react with&#x0201d;, &#x0201c;state change&#x0201d; (cut-point was set at 12%<xref rid="b12-ott-9-2317" ref-type="bibr">12</xref>), and &#x0201c;in same component&#x0201d;. A total of 33 genes were listed in the <italic>ITGA5</italic> or <italic>ITGB1</italic> gene networks (<xref ref-type="supplementary-material" rid="SD3-ott-9-2317">Table S3</xref>). In the univariate Cox regression model, <italic>PLAUR, PRKACA, ILK, YWHAZ, SPP1, PXN, LAMC1, TLN1</italic>, and <italic>CD9</italic> expressions were indicated as predictive of prognosis in patients with NSCLC in TCGA cohort (<italic>P</italic>&#x0003c;0.05, <xref ref-type="table" rid="t4-ott-9-2317">Table 4</xref>). Multivariate analysis, after adjusting for all potential prognostic factors, indicated that <italic>PLAUR</italic> (HR =1.16, 95% CI: 1.04&#x02013;1.30), <italic>ILK</italic> (HR =1.27, 95% CI: 1.00&#x02013;1.60), <italic>SPP1</italic> (HR =1.08, 95% CI: 1.02&#x02013;1.15), <italic>PXN</italic> (HR =1.25, 95% CI: 1.06&#x02013;1.48), and <italic>CD9</italic> (HR =0.83, 95% CI: 0.74&#x02013;0.94) were independent predictors of OS (all <italic>P</italic>&#x0003c;0.05, <xref ref-type="table" rid="t4-ott-9-2317">Table 4</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Dingemans et al had reported that ITGA5 and ITGB1 were prognostic factors in the early stage of NSCLC.<xref rid="b8-ott-9-2317" ref-type="bibr">8</xref> We validated their findings in a large cohort from TCGAdatabase. Aside from <italic>ITGA5</italic> and <italic>ITGB1, PLAUR, ILK, SPP1, PXN</italic>, and <italic>CD9</italic> were identified as independent predictors of OS in patients with NSCLC using gene network analysis.</p><p>As cell adhesion proteins, integrins play an important role in the cellular and extracellular environment to regulate attachment, survival, and motility.<xref rid="b13-ott-9-2317" ref-type="bibr">13</xref> Integrins are communicators between the cell and the extracellular environment.<xref rid="b5-ott-9-2317" ref-type="bibr">5</xref> Integrins can activate growth receptors and downstream cellular signals,<xref rid="b6-ott-9-2317" ref-type="bibr">6</xref> leading to cancer growth, metastasis, tumor angiogenesis, and resistance to radiotherapy and chemotherapy.<xref rid="b14-ott-9-2317" ref-type="bibr">14</xref>,<xref rid="b15-ott-9-2317" ref-type="bibr">15</xref> Integrin expression levels have been reported to correlate with prognosis in glioblastoma, cervical squamous cell cancer, ovarian cancer, gastric cancer, and melanoma.<xref rid="b13-ott-9-2317" ref-type="bibr">13</xref>,<xref rid="b16-ott-9-2317" ref-type="bibr">16</xref>&#x02013;<xref rid="b23-ott-9-2317" ref-type="bibr">23</xref> As drug targets, integrin inhibition enhances the cytotoxic efficacy of radiation and chemotherapy.<xref rid="b24-ott-9-2317" ref-type="bibr">24</xref>,<xref rid="b25-ott-9-2317" ref-type="bibr">25</xref> Several integrin inhibitors have entered clinical trials as cancer therapy agents.<xref rid="b26-ott-9-2317" ref-type="bibr">26</xref></p><p>Previous studies have reported an association between increased integrin alpha 5 expression and poor outcome in NSCLC.<xref rid="b8-ott-9-2317" ref-type="bibr">8</xref>,<xref rid="b27-ott-9-2317" ref-type="bibr">27</xref> More specifically, Adachi et al found that inlymph-node-negative patients with NSCLC, high ITGA5 expressers had a significantly worse 5-year survival. It was suggested that tumors that express high levels of ITGA5 were more prone to metastasis or had undetectable micrometastases at the time of surgery.<xref rid="b27-ott-9-2317" ref-type="bibr">27</xref> Other studies have also pointed to a relationship between ITGA5 and tumor metastasis. Valastyan et al reported that the downregulation of ITGA5 by miR-31 decreased breast cancer metastasis in vivo.<xref rid="b28-ott-9-2317" ref-type="bibr">28</xref> MiR-148b-mediated ITGA5 inhibition could also decrease lung metastasis formation.<xref rid="b29-ott-9-2317" ref-type="bibr">29</xref></p><p>The prognostic value of ITGB1 in NSCLC has been reported,<xref rid="b30-ott-9-2317" ref-type="bibr">30</xref> and it was shown to be correlated with lymph node metastasis.<xref rid="b31-ott-9-2317" ref-type="bibr">31</xref> ITGB1 inhibition has been shown to decrease lung cancer invasion and metastasis in vitro and in vivo.<xref rid="b32-ott-9-2317" ref-type="bibr">32</xref> Our work indicates a certain correlation between NSCLC outcome and the integrin gene family; however, the mechanism, which is likely to be complex, remains unclear. Further study is required.</p><p>Our study tried to answer several questions left unanswered in previous studies. We found that integrins were differently expressed in SCC and adenocarcinoma of lung cancer. The independent factors were different as well. They were ITGA6 in adenocarcinoma and ITGA3 in SCC. The diversity of independent prognostic factors of NSCLC was possible due to different expression patterns of SCC and adenocarcinoma. A previous study had shown that ITGA3 was upregulated in adenocarcinoma but not in SCC;<xref rid="b33-ott-9-2317" ref-type="bibr">33</xref> however, we found that the upregulation of <italic>ITGA3</italic> in SCC indicated poor prognosis. In adenocarcinoma, the <italic>ITGA3</italic> levels were relatively high with minor diversity. Another controversial topic is integrin and the metastatic potential of NSCLC. In our study, different subtypes of NSCLC demonstrated diverse integrins that were associated with metastasis. Only ITGA3 and ITGA5 were associated with NSCLC metastasis. ITGA5 was associated with lymph node metastasis of adenocarcinoma, which was possibly due to the role of ITGA5 in activating endothelial cells during tumor angiogenesis.<xref rid="b8-ott-9-2317" ref-type="bibr">8</xref> Furthermore, our study identified a new set of genes as NSCLC biomarkers or even therapeutic targets through <italic>ITGA5</italic> and <italic>ITGB1</italic> network analysis. Suppression PLAUR expression could decrease lung cancer lymph node metastasis.<xref rid="b34-ott-9-2317" ref-type="bibr">34</xref> ILK binds the cytoplasmic domain of beta integrins and regulates the integrin-mediated signal transduction. Its activity is important in epithelial-to-mesenchymal transition, and the overexpression of ILK has been implicated in tumor growth and metastasis via nuclear factor-&#x003ba;B signaling.<xref rid="b35-ott-9-2317" ref-type="bibr">35</xref> SPP1 encodes for the protein osteopontin, which is principally expressed in NSCLC tissues. SPP1 may be tightly regulated by the Ras oncogene<xref rid="b36-ott-9-2317" ref-type="bibr">36</xref> and is important in VEGF-mediated tumor angiogenesis.<xref rid="b37-ott-9-2317" ref-type="bibr">37</xref> PXN, which encodes for the protein paxillin, has been shown to be regulated by miR-218<xref rid="b38-ott-9-2317" ref-type="bibr">38</xref> and could make EGFR-mutant lung cancers resistant to tyrosine kinase inhibitor via modulating the stability of BIM and Mcl-1 proteins.<xref rid="b39-ott-9-2317" ref-type="bibr">39</xref></p><p>Different from the above four genes, <italic>CD9</italic> was a favorable factor in NSCLC outcome. This is supported by previous studies that showed that the low expression of CD9 may contribute to the early recurrence of NSCLC.<xref rid="b40-ott-9-2317" ref-type="bibr">40</xref> These studies suggested that the influence of integrins on the outcome of NSCLC might be via the regulation of epithelial-to-mesenchymal transition, tumor invasion, angiogenesis, and metastasis. These consistent results demonstrated that our method was applicable for detecting new prognostic indicators or even therapeutic targets.</p><p>In the study, all information was obtained from a large population with long-time follow-up and standard specimen collection and sequencing. The results were open-access, repeatable, and with high statistical power. However, there were certain limitations to our study. Although there was external validation previously,<xref rid="b8-ott-9-2317" ref-type="bibr">8</xref> we analyzed the correlationamong integrins and network gene expression and NSCLC OS only in TCGA cohort. The prognosis of NSCLC is affected by many factors, such as comorbidity, tumor stage, surgical performance, and response to radiation therapy and chemotherapy, so a single biomarker is not enough. In addition, information on ethnicity was not available in TCGA database. In conclusion, further mechanistic research will be required to understand in more detail the integrin family and its role in patients with NSCLC.</p></sec><sec><title>Conclusion</title><p><italic>ITGA5</italic> and <italic>ITGB1</italic> were identified as independent prognostic integrin markers associated with OS in NSCLC, and several outcome-related genes were determined through gene cluster analysis. This method could act as a tool to uncover more prognostic-associated genes and therapeutic targets in NSCLC.</p></sec><sec sec-type="supplementary-material"><title>Supplementary materials</title><supplementary-material content-type="local-data" id="SD1-ott-9-2317"><table-wrap id="ts1-ott-9-2317" position="float"><label>Table S1</label><caption><p>Gene IDs of integrin family and related genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Official gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Full name</th><th valign="top" align="left" rowspan="1" colspan="1">UniGene</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA1</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.644352</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA2</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.482077</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA2B</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.411312</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA3</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.265829</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA4</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.440955</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA5</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.505654</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA6</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 6</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.133397</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA7</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 7</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.524484</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA8</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 8</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.171311</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA9</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 9</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.113157</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA10</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 10</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.158237</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA11</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha 11</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.436416</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAD</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha D</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.679163</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAE</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1, alpha polypeptide)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.513867</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAL</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.174103</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAM</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha M (complement component 3 receptor 3 subunit)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.172631</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAV</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.436873</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAX</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, alpha X (complement component 3 receptor 4 subunit)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.248472</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.643813</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP1</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 1 binding protein 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.467662</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP2</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 1 binding protein (melusin) 2</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.109999</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP3</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 1 binding protein 3 (nicotinamide riboside kinase 2)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.135458</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB2</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.375957</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB3</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.218040</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB3BP</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 3 binding protein (beta 3-endonexin)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.166539</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB4</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 4</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.632226</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB5</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 5</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.536663</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB6</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 6</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.470399</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB7</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta 7</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.654470</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGBL1</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin, beta-like 1 (with EGF-like repeat domains)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.696554</td></tr></tbody></table></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD2-ott-9-2317"><table-wrap id="ts2-ott-9-2317" position="float"><label>Table S2</label><caption><p>Spearman&#x02019;s correlation analysis of integrin family and N stage and M stage of NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Gene</th><th colspan="4" valign="top" align="left" rowspan="1">Squamous cell carcinoma<hr/></th><th colspan="4" valign="top" align="left" rowspan="1">Adenocarcinoma
<hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">N (N=468)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">M (N=394)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">N (N=475)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">M (N=344)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Coefficient</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-ott-9-2317">*</xref></th><th valign="top" align="left" rowspan="1" colspan="1">Coefficient</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-ott-9-2317">*</xref></th><th valign="top" align="left" rowspan="1" colspan="1">Coefficient</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-ott-9-2317">*</xref></th><th valign="top" align="left" rowspan="1" colspan="1">Coefficient</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-ott-9-2317">*</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA1</td><td valign="top" align="left" rowspan="1" colspan="1">0.016</td><td valign="top" align="left" rowspan="1" colspan="1">0.733</td><td valign="top" align="left" rowspan="1" colspan="1">0.072</td><td valign="top" align="left" rowspan="1" colspan="1">0.153</td><td valign="top" align="left" rowspan="1" colspan="1">0.065</td><td valign="top" align="left" rowspan="1" colspan="1">0.156</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.025</td><td valign="top" align="left" rowspan="1" colspan="1">0.643</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.047</td><td valign="top" align="left" rowspan="1" colspan="1">0.308</td><td valign="top" align="left" rowspan="1" colspan="1">0.039</td><td valign="top" align="left" rowspan="1" colspan="1">0.443</td><td valign="top" align="left" rowspan="1" colspan="1">0.074</td><td valign="top" align="left" rowspan="1" colspan="1">0.105</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.015</td><td valign="top" align="left" rowspan="1" colspan="1">0.779</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA2B</td><td valign="top" align="left" rowspan="1" colspan="1">0.034</td><td valign="top" align="left" rowspan="1" colspan="1">0.469</td><td valign="top" align="left" rowspan="1" colspan="1">0.006</td><td valign="top" align="left" rowspan="1" colspan="1">0.911</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.129</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.956</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA3</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.098</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">0.041</td><td valign="top" align="left" rowspan="1" colspan="1">0.412</td><td valign="top" align="left" rowspan="1" colspan="1">0.051</td><td valign="top" align="left" rowspan="1" colspan="1">0.264</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.107</td><td valign="top" align="left" rowspan="1" colspan="1">0.047</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA4</td><td valign="top" align="left" rowspan="1" colspan="1">0.013</td><td valign="top" align="left" rowspan="1" colspan="1">0.780</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.988</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.068</td><td valign="top" align="left" rowspan="1" colspan="1">0.140</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.084</td><td valign="top" align="left" rowspan="1" colspan="1">0.118</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.068</td><td valign="top" align="left" rowspan="1" colspan="1">0.142</td><td valign="top" align="left" rowspan="1" colspan="1">0.049</td><td valign="top" align="left" rowspan="1" colspan="1">0.328</td><td valign="top" align="left" rowspan="1" colspan="1">0.113</td><td valign="top" align="left" rowspan="1" colspan="1">0.014</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.019</td><td valign="top" align="left" rowspan="1" colspan="1">0.721</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA6</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.033</td><td valign="top" align="left" rowspan="1" colspan="1">0.471</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.032</td><td valign="top" align="left" rowspan="1" colspan="1">0.532</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.943</td><td valign="top" align="left" rowspan="1" colspan="1">0.030</td><td valign="top" align="left" rowspan="1" colspan="1">0.574</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA7</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.016</td><td valign="top" align="left" rowspan="1" colspan="1">0.738</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.166</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.134</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.035</td><td valign="top" align="left" rowspan="1" colspan="1">0.514</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA8</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.052</td><td valign="top" align="left" rowspan="1" colspan="1">0.261</td><td valign="top" align="left" rowspan="1" colspan="1">0.064</td><td valign="top" align="left" rowspan="1" colspan="1">0.205</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.086</td><td valign="top" align="left" rowspan="1" colspan="1">0.062</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.048</td><td valign="top" align="left" rowspan="1" colspan="1">0.370</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA9</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.028</td><td valign="top" align="left" rowspan="1" colspan="1">0.546</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.018</td><td valign="top" align="left" rowspan="1" colspan="1">0.714</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.132</td><td valign="top" align="left" rowspan="1" colspan="1">0.004</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.035</td><td valign="top" align="left" rowspan="1" colspan="1">0.517</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA10</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.055</td><td valign="top" align="left" rowspan="1" colspan="1">0.237</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">0.972</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.083</td><td valign="top" align="left" rowspan="1" colspan="1">0.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.080</td><td valign="top" align="left" rowspan="1" colspan="1">0.139</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGA11</td><td valign="top" align="left" rowspan="1" colspan="1">0.017</td><td valign="top" align="left" rowspan="1" colspan="1">0.709</td><td valign="top" align="left" rowspan="1" colspan="1">0.048</td><td valign="top" align="left" rowspan="1" colspan="1">0.343</td><td valign="top" align="left" rowspan="1" colspan="1">0.075</td><td valign="top" align="left" rowspan="1" colspan="1">0.105</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.097</td><td valign="top" align="left" rowspan="1" colspan="1">0.072</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAD</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.032</td><td valign="top" align="left" rowspan="1" colspan="1">0.489</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.058</td><td valign="top" align="left" rowspan="1" colspan="1">0.248</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.154</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.053</td><td valign="top" align="left" rowspan="1" colspan="1">0.326</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAE</td><td valign="top" align="left" rowspan="1" colspan="1">0.090</td><td valign="top" align="left" rowspan="1" colspan="1">0.051</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.084</td><td valign="top" align="left" rowspan="1" colspan="1">0.097</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.047</td><td valign="top" align="left" rowspan="1" colspan="1">0.304</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.043</td><td valign="top" align="left" rowspan="1" colspan="1">0.427</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAL</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td><td valign="top" align="left" rowspan="1" colspan="1">0.790</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.056</td><td valign="top" align="left" rowspan="1" colspan="1">0.269</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.102</td><td valign="top" align="left" rowspan="1" colspan="1">0.026</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.069</td><td valign="top" align="left" rowspan="1" colspan="1">0.203</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAM</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.027</td><td valign="top" align="left" rowspan="1" colspan="1">0.559</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.036</td><td valign="top" align="left" rowspan="1" colspan="1">0.473</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.037</td><td valign="top" align="left" rowspan="1" colspan="1">0.422</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.085</td><td valign="top" align="left" rowspan="1" colspan="1">0.116</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAV</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.088</td><td valign="top" align="left" rowspan="1" colspan="1">0.058</td><td valign="top" align="left" rowspan="1" colspan="1">0.089</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td><td valign="top" align="left" rowspan="1" colspan="1">0.092</td><td valign="top" align="left" rowspan="1" colspan="1">0.045</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.192</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGAX</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.037</td><td valign="top" align="left" rowspan="1" colspan="1">0.420</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.004</td><td valign="top" align="left" rowspan="1" colspan="1">0.929</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.072</td><td valign="top" align="left" rowspan="1" colspan="1">0.116</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.050</td><td valign="top" align="left" rowspan="1" colspan="1">0.353</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.040</td><td valign="top" align="left" rowspan="1" colspan="1">0.384</td><td valign="top" align="left" rowspan="1" colspan="1">0.111</td><td valign="top" align="left" rowspan="1" colspan="1">0.028</td><td valign="top" align="left" rowspan="1" colspan="1">0.046</td><td valign="top" align="left" rowspan="1" colspan="1">0.319</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td><td valign="top" align="left" rowspan="1" colspan="1">0.993</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP1</td><td valign="top" align="left" rowspan="1" colspan="1">0.080</td><td valign="top" align="left" rowspan="1" colspan="1">0.083</td><td valign="top" align="left" rowspan="1" colspan="1">0.068</td><td valign="top" align="left" rowspan="1" colspan="1">0.179</td><td valign="top" align="left" rowspan="1" colspan="1">0.054</td><td valign="top" align="left" rowspan="1" colspan="1">0.242</td><td valign="top" align="left" rowspan="1" colspan="1">0.006</td><td valign="top" align="left" rowspan="1" colspan="1">0.917</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP3</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.026</td><td valign="top" align="left" rowspan="1" colspan="1">0.577</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.077</td><td valign="top" align="left" rowspan="1" colspan="1">0.125</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.077</td><td valign="top" align="left" rowspan="1" colspan="1">0.095</td><td valign="top" align="left" rowspan="1" colspan="1">0.128</td><td valign="top" align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB1BP2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.089</td><td valign="top" align="left" rowspan="1" colspan="1">0.054</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.014</td><td valign="top" align="left" rowspan="1" colspan="1">0.776</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.011</td><td valign="top" align="left" rowspan="1" colspan="1">0.814</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.088</td><td valign="top" align="left" rowspan="1" colspan="1">0.105</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB2</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td><td valign="top" align="left" rowspan="1" colspan="1">0.802</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.062</td><td valign="top" align="left" rowspan="1" colspan="1">0.220</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.027</td><td valign="top" align="left" rowspan="1" colspan="1">0.562</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.099</td><td valign="top" align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB3</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.079</td><td valign="top" align="left" rowspan="1" colspan="1">0.086</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">0.488</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td><td valign="top" align="left" rowspan="1" colspan="1">0.122</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.071</td><td valign="top" align="left" rowspan="1" colspan="1">0.187</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB3BP</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.042</td><td valign="top" align="left" rowspan="1" colspan="1">0.366</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.019</td><td valign="top" align="left" rowspan="1" colspan="1">0.702</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.021</td><td valign="top" align="left" rowspan="1" colspan="1">0.641</td><td valign="top" align="left" rowspan="1" colspan="1">0.097</td><td valign="top" align="left" rowspan="1" colspan="1">0.072</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB4</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td><td valign="top" align="left" rowspan="1" colspan="1">0.872</td><td valign="top" align="left" rowspan="1" colspan="1">0.062</td><td valign="top" align="left" rowspan="1" colspan="1">0.218</td><td valign="top" align="left" rowspan="1" colspan="1">0.076</td><td valign="top" align="left" rowspan="1" colspan="1">0.096</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.040</td><td valign="top" align="left" rowspan="1" colspan="1">0.465</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.094</td><td valign="top" align="left" rowspan="1" colspan="1">0.041</td><td valign="top" align="left" rowspan="1" colspan="1">0.059</td><td valign="top" align="left" rowspan="1" colspan="1">0.245</td><td valign="top" align="left" rowspan="1" colspan="1">0.022</td><td valign="top" align="left" rowspan="1" colspan="1">0.626</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.114</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB6</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.140</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">0.080</td><td valign="top" align="left" rowspan="1" colspan="1">0.112</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.953</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.033</td><td valign="top" align="left" rowspan="1" colspan="1">0.548</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB7</td><td valign="top" align="left" rowspan="1" colspan="1">0.016</td><td valign="top" align="left" rowspan="1" colspan="1">0.734</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.083</td><td valign="top" align="left" rowspan="1" colspan="1">0.099</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.063</td><td valign="top" align="left" rowspan="1" colspan="1">0.173</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.083</td><td valign="top" align="left" rowspan="1" colspan="1">0.126</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGB8</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.116</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td><td valign="top" align="left" rowspan="1" colspan="1">0.029</td><td valign="top" align="left" rowspan="1" colspan="1">0.566</td><td valign="top" align="left" rowspan="1" colspan="1">0.009</td><td valign="top" align="left" rowspan="1" colspan="1">0.852</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.036</td><td valign="top" align="left" rowspan="1" colspan="1">0.502</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ITGBL1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.005</td><td valign="top" align="left" rowspan="1" colspan="1">0.914</td><td valign="top" align="left" rowspan="1" colspan="1">0.082</td><td valign="top" align="left" rowspan="1" colspan="1">0.106</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.126</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.115</td><td valign="top" align="left" rowspan="1" colspan="1">0.032</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn12-ott-9-2317"><label>*</label><p>Bold type indicates statistical significance.</p></fn><fn id="tfn13-ott-9-2317"><p><bold>Abbreviations:</bold> M, M stage; N, N stage; NSCLC, non-small-cell lung cancer.</p></fn></table-wrap-foot></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD3-ott-9-2317"><table-wrap id="ts3-ott-9-2317" position="float"><label>Table S3</label><caption><p>Gene IDs of ITGA5 and ITGB1 network genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Official gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Full name</th><th valign="top" align="left" rowspan="1" colspan="1">UniGene</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">ABI1</td><td valign="top" align="left" rowspan="1" colspan="1">abl-interactor 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.508148</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADAM15</td><td valign="top" align="left" rowspan="1" colspan="1">ADAM metallopeptidase domain 15</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.312098</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ARHGAP5</td><td valign="top" align="left" rowspan="1" colspan="1">Rho GTPase-activating protein 5</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.592313</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD81</td><td valign="top" align="left" rowspan="1" colspan="1">CD81 molecule</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.54457</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD9</td><td valign="top" align="left" rowspan="1" colspan="1">CD9 molecule</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.114286</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL18A1</td><td valign="top" align="left" rowspan="1" colspan="1">Collagen, type XVIII, alpha 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.517356</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EGFR</td><td valign="top" align="left" rowspan="1" colspan="1">Epidermal growth factor receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.488293</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EPS8</td><td valign="top" align="left" rowspan="1" colspan="1">Epidermal growth factor receptor pathway substrate 8</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.591160</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ERBB2</td><td valign="top" align="left" rowspan="1" colspan="1">v-erb-b2 erythroblastic leukemia viral oncogene homolog 2</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.446352</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GIPC1</td><td valign="top" align="left" rowspan="1" colspan="1">GIPC PDZ domain containing family, member 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.655012</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IGF1R</td><td valign="top" align="left" rowspan="1" colspan="1">Insulin-like growth factor 1 receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.643120</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ILK</td><td valign="top" align="left" rowspan="1" colspan="1">Integrin-linked kinase</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.706355</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMB2</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin, beta 2 (laminin S)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.439726</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMC1</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin, gamma 1 (formerly LAMB2)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.609663</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PLAUR</td><td valign="top" align="left" rowspan="1" colspan="1">Plasminogen activator, urokinase receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.466871</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKACA</td><td valign="top" align="left" rowspan="1" colspan="1">Protein kinase, cAMP-dependent, catalytic, alpha</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.631630</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKAR1A</td><td valign="top" align="left" rowspan="1" colspan="1">Protein kinase, cAMP-dependent, regulatory, type I, alpha</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.280342</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKAR1B</td><td valign="top" align="left" rowspan="1" colspan="1">Protein kinase, cAMP-dependent, regulatory, type I, beta</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.520851</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKCA</td><td valign="top" align="left" rowspan="1" colspan="1">Protein kinase C, alpha</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.531704</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTK2</td><td valign="top" align="left" rowspan="1" colspan="1">PTK2 protein tyrosine kinase 2</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.395482</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTK2B</td><td valign="top" align="left" rowspan="1" colspan="1">PTK2B protein tyrosine kinase 2 beta</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.491322</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTPRA</td><td valign="top" align="left" rowspan="1" colspan="1">Protein tyrosine phosphatase, receptor type, A</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.269577</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PXN</td><td valign="top" align="left" rowspan="1" colspan="1">Paxillin</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.446336</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RAC1</td><td valign="top" align="left" rowspan="1" colspan="1">Ras-related C3 botulinum toxin substrate 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.413812</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RPS6KB1</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein S6 kinase, 70 kDa, polypeptide 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.463642</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDC2</td><td valign="top" align="left" rowspan="1" colspan="1">Syndecan 2</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.1501</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDC4</td><td valign="top" align="left" rowspan="1" colspan="1">Syndecan 4</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.632267</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SPP1</td><td valign="top" align="left" rowspan="1" colspan="1">Secreted phosphoprotein 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.313</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SRC</td><td valign="top" align="left" rowspan="1" colspan="1">v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.195659</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLN1</td><td valign="top" align="left" rowspan="1" colspan="1">Talin 1</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.471014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VEGFA</td><td valign="top" align="left" rowspan="1" colspan="1">Vascular endothelial growth factor A</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.73793</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VLDLR</td><td valign="top" align="left" rowspan="1" colspan="1">Very low density lipoprotein receptor</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.370422</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">YWHAZ</td><td valign="top" align="left" rowspan="1" colspan="1">Tryptophan 5-monooxygenase activation protein, zeta polypeptide</td><td valign="top" align="left" rowspan="1" colspan="1">Hs.492407</td></tr></tbody></table><table-wrap-foot><fn id="tfn14-ott-9-2317"><p><bold>Abbreviation:</bold> EGFR, epidermal growth factor receptor.</p></fn></table-wrap-foot></table-wrap></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely thank Dr Wan Fangning, Fudan University Shanghai Cancer Center, for providing bioinformatics support for this article.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors declare no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ott-9-2317"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><issue>2</issue><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="b2-ott-9-2317"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>Epidemiology of lung cancer prognosis: quantity and quality of life</article-title><source>Methods Mol Biol</source><year>2009</year><volume>471</volume><fpage>469</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19109795</pub-id></element-citation></ref><ref id="b3-ott-9-2317"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desgrosellier</surname><given-names>JS</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><article-title>Integrins in cancer: biological implications and therapeutic opportunities</article-title><source>Nat Rev Cancer</source><year>2010</year><volume>10</volume><issue>1</issue><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20029421</pub-id></element-citation></ref><ref id="b4-ott-9-2317"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Ginsberg</surname><given-names>MH</given-names></name></person-group><article-title>Networks and crosstalk: integrin signalling spreads</article-title><source>Nat Cell Biol</source><year>2002</year><volume>4</volume><issue>4</issue><fpage>E65</fpage><lpage>E68</lpage><pub-id pub-id-type="pmid">11944032</pub-id></element-citation></ref><ref id="b5-ott-9-2317"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Integrins: bidirectional, allosteric signaling machines</article-title><source>Cell</source><year>2002</year><volume>110</volume><issue>6</issue><fpage>673</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">12297042</pub-id></element-citation></ref><ref id="b6-ott-9-2317"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehlgans</surname><given-names>S</given-names></name><name><surname>Haase</surname><given-names>M</given-names></name><name><surname>Cordes</surname><given-names>N</given-names></name></person-group><article-title>Signalling via integrins: implications for cell survival and anticancer strategies</article-title><source>Biochim Biophys Acta</source><year>2007</year><volume>1775</volume><issue>1</issue><fpage>163</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">17084981</pub-id></element-citation></ref><ref id="b7-ott-9-2317"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steuer</surname><given-names>CE</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name></person-group><article-title>Targeting EGFR in lung cancer: lessons learned and future perspectives</article-title><source>Mol Aspects Med</source><year>2015</year><volume>45</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">26022942</pub-id></element-citation></ref><ref id="b8-ott-9-2317"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingemans</surname><given-names>AM</given-names></name><name><surname>van den Boogaart</surname><given-names>V</given-names></name><name><surname>Vosse</surname><given-names>BA</given-names></name><name><surname>van Suylen</surname><given-names>RJ</given-names></name><name><surname>Griffioen</surname><given-names>AW</given-names></name><name><surname>Thijssen</surname><given-names>VL</given-names></name></person-group><article-title>Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>152</fpage><pub-id pub-id-type="pmid">20565758</pub-id></element-citation></ref><ref id="b9-ott-9-2317"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Shia</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name></person-group><article-title>Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA</article-title><source>Brief Bioinform</source><year>2015</year><volume>16</volume><issue>2</issue><fpage>291</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">24632304</pub-id></element-citation></ref><ref id="b10-ott-9-2317"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title><source>Nature</source><year>2014</year><volume>511</volume><issue>7511</issue><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">25079552</pub-id></element-citation></ref><ref id="b11-ott-9-2317"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>JM</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Leavitt</surname><given-names>L</given-names></name><name><surname>Hallahan</surname><given-names>DE</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>65</volume><issue>5</issue><fpage>1536</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">16863930</pub-id></element-citation></ref><ref id="b12-ott-9-2317"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Dai</surname><given-names>BL</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation</article-title><source>Cell Death Dis</source><year>2012</year><volume>3</volume><fpage>e406</fpage><pub-id pub-id-type="pmid">23059825</pub-id></element-citation></ref><ref id="b13-ott-9-2317"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZY</given-names></name><name><surname>Xu</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2008</year><volume>20</volume><issue>1</issue><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17981018</pub-id></element-citation></ref><ref id="b14-ott-9-2317"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchaicha</surname><given-names>JH</given-names></name><name><surname>Mobley</surname><given-names>AK</given-names></name><name><surname>Hossain</surname><given-names>MG</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>McCarty</surname><given-names>JH</given-names></name></person-group><article-title>A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><issue>31</issue><fpage>4460</fpage><lpage>4472</lpage><pub-id pub-id-type="pmid">20531304</pub-id></element-citation></ref><ref id="b15-ott-9-2317"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zutter</surname><given-names>MM</given-names></name></person-group><article-title>Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance</article-title><source>Adv Exp Med Biol</source><year>2007</year><volume>608</volume><fpage>87</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">17993234</pub-id></element-citation></ref><ref id="b16-ott-9-2317"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Riley</surname><given-names>C</given-names></name><name><surname>Rice</surname><given-names>GE</given-names></name><name><surname>Quinn</surname><given-names>MA</given-names></name><name><surname>Baker</surname><given-names>MS</given-names></name></person-group><article-title>Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer</article-title><source>J Histochem Cytochem</source><year>2002</year><volume>50</volume><issue>10</issue><fpage>1371</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">12364570</pub-id></element-citation></ref><ref id="b17-ott-9-2317"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elayadi</surname><given-names>AN</given-names></name><name><surname>Samli</surname><given-names>KN</given-names></name><name><surname>Prudkin</surname><given-names>L</given-names></name><etal/></person-group><article-title>A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>12</issue><fpage>5889</fpage><lpage>5895</lpage><pub-id pub-id-type="pmid">17575158</pub-id></element-citation></ref><ref id="b18-ott-9-2317"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>I</given-names></name><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Reich</surname><given-names>R</given-names></name><etal/></person-group><article-title>Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><issue>12</issue><fpage>4073</fpage><lpage>4079</lpage><pub-id pub-id-type="pmid">11751504</pub-id></element-citation></ref><ref id="b19-ott-9-2317"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageshita</surname><given-names>T</given-names></name><name><surname>Hamby</surname><given-names>CV</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name></person-group><article-title>Alpha(v) beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis</article-title><source>Cancer Immunol Immunother</source><year>2000</year><volume>49</volume><issue>6</issue><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">10946813</pub-id></element-citation></ref><ref id="b20-ott-9-2317"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazelbag</surname><given-names>S</given-names></name><name><surname>Kenter</surname><given-names>GG</given-names></name><name><surname>Gorter</surname><given-names>A</given-names></name><etal/></person-group><article-title>Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival</article-title><source>J Pathol</source><year>2007</year><volume>212</volume><issue>3</issue><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">17503414</pub-id></element-citation></ref><ref id="b21-ott-9-2317"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikkola</surname><given-names>J</given-names></name><name><surname>Vihinen</surname><given-names>P</given-names></name><name><surname>Vlaykova</surname><given-names>T</given-names></name><name><surname>Hahka-Kemppinen</surname><given-names>M</given-names></name><name><surname>Heino</surname><given-names>J</given-names></name><name><surname>Pyrhonen</surname><given-names>S</given-names></name></person-group><article-title>Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma</article-title><source>Melanoma Res</source><year>2004</year><volume>14</volume><issue>1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">15091191</pub-id></element-citation></ref><ref id="b22-ott-9-2317"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schittenhelm</surname><given-names>J</given-names></name><name><surname>Schwab</surname><given-names>EI</given-names></name><name><surname>Sperveslage</surname><given-names>J</given-names></name><etal/></person-group><article-title>Longitudinal expression analysis of alphav integrins in human gliomas reveals upregulation of integrin alphavbeta3 as a negative prognostic factor</article-title><source>J Neuropathol Exp Neurol</source><year>2013</year><volume>72</volume><issue>3</issue><fpage>194</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">23399898</pub-id></element-citation></ref><ref id="b23-ott-9-2317"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellon</surname><given-names>L</given-names></name><name><surname>Menendez</surname><given-names>JA</given-names></name><name><surname>Lupu</surname><given-names>R</given-names></name></person-group><article-title>AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>23</issue><fpage>3759</fpage><lpage>3773</lpage><pub-id pub-id-type="pmid">15782133</pub-id></element-citation></ref><ref id="b24-ott-9-2317"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname><given-names>T</given-names></name><name><surname>Brodie</surname><given-names>C</given-names></name><name><surname>Finniss</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency</article-title><source>Int J Cancer</source><year>2009</year><volume>124</volume><issue>11</issue><fpage>2719</fpage><lpage>2727</lpage><pub-id pub-id-type="pmid">19199360</pub-id></element-citation></ref><ref id="b25-ott-9-2317"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>JM</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>G</given-names></name><name><surname>Leavitt</surname><given-names>L</given-names></name><name><surname>Hallahan</surname><given-names>DE</given-names></name><name><surname>Bo</surname><given-names>L</given-names></name></person-group><article-title>Integrin alpha(V)beta(3) antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models</article-title><source>Int J Radiat Oncol</source><year>2006</year><volume>65</volume><issue>5</issue><fpage>1536</fpage><lpage>1543</lpage></element-citation></ref><ref id="b26-ott-9-2317"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>SL</given-names></name><name><surname>Picard</surname><given-names>M</given-names></name></person-group><article-title>Integrins as therapeutic targets</article-title><source>Trends Pharmacol Sci</source><year>2012</year><volume>33</volume><issue>7</issue><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">22633092</pub-id></element-citation></ref><ref id="b27-ott-9-2317"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Taki</surname><given-names>T</given-names></name><name><surname>Higashiyama</surname><given-names>M</given-names></name><name><surname>Kohno</surname><given-names>N</given-names></name><name><surname>Inufusa</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name></person-group><article-title>Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><issue>1</issue><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">10656437</pub-id></element-citation></ref><ref id="b28-ott-9-2317"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Benaich</surname><given-names>N</given-names></name><name><surname>Reinhardt</surname><given-names>F</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>12</issue><fpage>5147</fpage><lpage>5154</lpage><pub-id pub-id-type="pmid">20530680</pub-id></element-citation></ref><ref id="b29-ott-9-2317"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimino</surname><given-names>D</given-names></name><name><surname>De Pitta</surname><given-names>C</given-names></name><name><surname>Orso</surname><given-names>F</given-names></name><etal/></person-group><article-title>miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><issue>3</issue><fpage>1223</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">23233531</pub-id></element-citation></ref><ref id="b30-ott-9-2317"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>M</given-names></name><name><surname>Yamaji</surname><given-names>S</given-names></name><name><surname>Nagashima</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer</article-title><source>Hum Pathol</source><year>2007</year><volume>38</volume><issue>7</issue><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">17442374</pub-id></element-citation></ref><ref id="b31-ott-9-2317"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Yoo</surname><given-names>NJ</given-names></name></person-group><article-title>Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis</article-title><source>Lung Cancer</source><year>2003</year><volume>41</volume><issue>1</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12826314</pub-id></element-citation></ref><ref id="b32-ott-9-2317"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>MX</given-names></name><etal/></person-group><article-title>Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>e55714</fpage><pub-id pub-id-type="pmid">23441154</pub-id></element-citation></ref><ref id="b33-ott-9-2317"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boelens</surname><given-names>MC</given-names></name><name><surname>van den Berg</surname><given-names>A</given-names></name><name><surname>Vogelzang</surname><given-names>I</given-names></name><etal/></person-group><article-title>Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus</article-title><source>J Clin Pathol</source><year>2007</year><volume>60</volume><issue>6</issue><fpage>608</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">16489176</pub-id></element-citation></ref><ref id="b34-ott-9-2317"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichiki</surname><given-names>K</given-names></name><name><surname>Mitani</surname><given-names>N</given-names></name><name><surname>Doki</surname><given-names>Y</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Misaki</surname><given-names>T</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name></person-group><article-title>Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer</article-title><source>Clin Exp Metastasis</source><year>2000</year><volume>18</volume><issue>7</issue><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">11688958</pub-id></element-citation></ref><ref id="b35-ott-9-2317"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Overexpression of integrin-linked kinase (ILK) promotes migration and invasion of colorectal cancer cells by inducing epithelial-mesenchymal transition via NF-kappaB signaling</article-title><source>Acta Histochem</source><year>2014</year><volume>116</volume><issue>3</issue><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">24360977</pub-id></element-citation></ref><ref id="b36-ott-9-2317"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Differential osteopontin expression in lung cancer</article-title><source>Cancer Lett</source><year>2001</year><volume>171</volume><issue>2</issue><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">11520606</pub-id></element-citation></ref><ref id="b37-ott-9-2317"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shijubo</surname><given-names>N</given-names></name><name><surname>Uede</surname><given-names>T</given-names></name><name><surname>Kon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><issue>4</issue><fpage>1269</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">10508818</pub-id></element-citation></ref><ref id="b38-ott-9-2317"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DW</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>24</issue><fpage>10392</fpage><lpage>10401</lpage><pub-id pub-id-type="pmid">21159652</pub-id></element-citation></ref><ref id="b39-ott-9-2317"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DW</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chu</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability</article-title><source>Oncogene</source><comment>Epub</comment><month>4</month><day>27</day><year>2015</year></element-citation></ref><ref id="b40-ott-9-2317"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashiyama</surname><given-names>M</given-names></name><name><surname>Taki</surname><given-names>T</given-names></name><name><surname>Ieki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><issue>24</issue><fpage>6040</fpage><lpage>6044</lpage><pub-id pub-id-type="pmid">8521390</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ott-9-2317" position="float"><label>Figure 1</label><caption><p>Kaplan&#x02013;Meier plots of survival are shown according to ITGA5 and ITGB1 expression.</p><p><bold>Notes:</bold> (<bold>A</bold> and <bold>B</bold>) Kaplan&#x02013;Meier estimates of OS are shown according to the expression level of ITGA5 and ITGB1.</p><p><bold>Abbreviations:</bold> NSCLC, non-small-cell lung cancer; OS, overall survival.</p></caption><graphic xlink:href="ott-9-2317Fig1"/></fig><fig id="f2-ott-9-2317" position="float"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier estimates of overall survival according to ITGA5 expression, ITGB1 expression, and pathological histology.</p><p><bold>Notes:</bold> (<bold>A</bold> and <bold>B</bold>) Kaplan&#x02013;Meier estimates of OS were plotted according to ITGA5 expression in adenocarcinoma and squamous cell carcinoma. (<bold>C</bold> and <bold>D</bold>) Kaplan&#x02013;Meier estimates of OS were demonstrated according to ITGB1 expression in adenocarcinoma and squamous cell carcinoma.</p><p><bold>Abbreviation:</bold> OS, overall survival.</p></caption><graphic xlink:href="ott-9-2317Fig2"/></fig><fig id="f3-ott-9-2317" position="float"><label>Figure 3</label><caption><p>Interaction network building of ITGA5 and ITGB1.</p><p><bold>Notes:</bold> The situations selected for building the networks were stated as &#x0201c;react with&#x0201d; (purple line), &#x0201c;in same component&#x0201d; (brown line), and &#x0201c;state change&#x0201d; (green arrow). The cut-off point of state change was set as 12%. (<bold>A</bold>) The network of ITGA5 and (<bold>B</bold>) the network of ITGB1.</p></caption><graphic xlink:href="ott-9-2317Fig3"/></fig><table-wrap id="t1-ott-9-2317" position="float"><label>Table 1</label><caption><p>Clinical characteristics of patients with NSCLC in TCGA cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variables</th><th valign="top" align="left" rowspan="1" colspan="1">Number</th><th valign="top" align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of patients</td><td valign="top" align="left" rowspan="1" colspan="1">959</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, median (range)</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">(38&#x02013;90)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">576</td><td valign="top" align="left" rowspan="1" colspan="1">60.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">383</td><td valign="top" align="left" rowspan="1" colspan="1">39.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Histology</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">485</td><td valign="top" align="left" rowspan="1" colspan="1">50.60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">474</td><td valign="top" align="left" rowspan="1" colspan="1">49.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pT</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;T1</td><td valign="top" align="left" rowspan="1" colspan="1">270</td><td valign="top" align="left" rowspan="1" colspan="1">28.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;T2</td><td valign="top" align="left" rowspan="1" colspan="1">538</td><td valign="top" align="left" rowspan="1" colspan="1">56.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;T3</td><td valign="top" align="left" rowspan="1" colspan="1">110</td><td valign="top" align="left" rowspan="1" colspan="1">11.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;T4</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">4.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Tx</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;N0</td><td valign="top" align="left" rowspan="1" colspan="1">612</td><td valign="top" align="left" rowspan="1" colspan="1">63.80</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;N1</td><td valign="top" align="left" rowspan="1" colspan="1">216</td><td valign="top" align="left" rowspan="1" colspan="1">22.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;N2</td><td valign="top" align="left" rowspan="1" colspan="1">108</td><td valign="top" align="left" rowspan="1" colspan="1">11.30</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;N3</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nx</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">1.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">M</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;M0</td><td valign="top" align="left" rowspan="1" colspan="1">707</td><td valign="top" align="left" rowspan="1" colspan="1">73.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;M1</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">3.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mx</td><td valign="top" align="left" rowspan="1" colspan="1">221</td><td valign="top" align="left" rowspan="1" colspan="1">23.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;I</td><td valign="top" align="left" rowspan="1" colspan="1">495</td><td valign="top" align="left" rowspan="1" colspan="1">51.60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;II</td><td valign="top" align="left" rowspan="1" colspan="1">269</td><td valign="top" align="left" rowspan="1" colspan="1">28.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;III</td><td valign="top" align="left" rowspan="1" colspan="1">163</td><td valign="top" align="left" rowspan="1" colspan="1">17.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IV</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">3.30</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nonsmoker</td><td valign="top" align="left" rowspan="1" colspan="1">86</td><td valign="top" align="left" rowspan="1" colspan="1">9.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Reformed smoker</td><td valign="top" align="left" rowspan="1" colspan="1">608</td><td valign="top" align="left" rowspan="1" colspan="1">63.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Current smoker</td><td valign="top" align="left" rowspan="1" colspan="1">244</td><td valign="top" align="left" rowspan="1" colspan="1">25.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of neoadjuvant therapy</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">949</td><td valign="top" align="left" rowspan="1" colspan="1">99.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of radiation therapy</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">94</td><td valign="top" align="left" rowspan="1" colspan="1">9.80</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">641</td><td valign="top" align="left" rowspan="1" colspan="1">66.80</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Undefined</td><td valign="top" align="left" rowspan="1" colspan="1">224</td><td valign="top" align="left" rowspan="1" colspan="1">23.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Median OS in months (range)</td><td valign="top" align="left" rowspan="1" colspan="1">16.7</td><td valign="top" align="left" rowspan="1" colspan="1">(0.5&#x02013;83.3)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ott-9-2317"><p><bold>Note:</bold> Figures are expressed as percentage unless range (shown in parentheses).</p></fn><fn id="tfn2-ott-9-2317"><p><bold>Abbreviations:</bold> M, M stage; N, N stage; NSCLC, non-small-cell lung cancer; OS, overall survival; pT, pathological T stage; TCGA, The Cancer Genome Atlas.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ott-9-2317" position="float"><label>Table 2</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of integrin expression and overall survival for patients with NSCLC in TCGA cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene</th><th colspan="3" valign="top" align="left" rowspan="1">Univariate
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Multivariate<xref ref-type="table-fn" rid="tfn3-ott-9-2317">a</xref>
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA8</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.96&#x02013;1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">0.736</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA9</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">0.830</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.11</td><td valign="top" align="left" rowspan="1" colspan="1">(1.01&#x02013;1.23)</td><td valign="top" align="left" rowspan="1" colspan="1">0.039<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.10</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.25)</td><td valign="top" align="left" rowspan="1" colspan="1">0.132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.07</td><td valign="top" align="left" rowspan="1" colspan="1">(0.99&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.070</td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">0.760</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.148</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA4</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">(0.91&#x02013;1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.989</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.21</td><td valign="top" align="left" rowspan="1" colspan="1">(1.10&#x02013;1.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.17</td><td valign="top" align="left" rowspan="1" colspan="1">(1.05&#x02013;1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.09</td><td valign="top" align="left" rowspan="1" colspan="1">(1.03&#x02013;1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.09</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.22)</td><td valign="top" align="left" rowspan="1" colspan="1">0.123</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1">(0.91&#x02013;1.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.911</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAX</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">(0.91&#x02013;1.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.926</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAV</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.10</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">0.127</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAL</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.96</td><td valign="top" align="left" rowspan="1" colspan="1">(0.89&#x02013;1.04)</td><td valign="top" align="left" rowspan="1" colspan="1">0.338</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAM</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.04</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">0.298</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA2B</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.95</td><td valign="top" align="left" rowspan="1" colspan="1">(0.88&#x02013;1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.109</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">(0.80&#x02013;1.21)</td><td valign="top" align="left" rowspan="1" colspan="1">0.868</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1">(0.80&#x02013;1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.427</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">(0.88&#x02013;1.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.637</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAD</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1">(0.87&#x02013;1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.091</td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1">(0.86&#x02013;1.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAE</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td><td valign="top" align="left" rowspan="1" colspan="1">(0.83&#x02013;1.13)</td><td valign="top" align="left" rowspan="1" colspan="1">0.683</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGBL1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.05</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">0.149</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB3BP</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.95</td><td valign="top" align="left" rowspan="1" colspan="1">(0.82&#x02013;1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">0.550</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.41</td><td valign="top" align="left" rowspan="1" colspan="1">(1.21&#x02013;1.64)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.31</td><td valign="top" align="left" rowspan="1" colspan="1">(1.10&#x02013;1.55)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.03</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.271</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.11</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.27)</td><td valign="top" align="left" rowspan="1" colspan="1">0.102</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB4</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.11</td><td valign="top" align="left" rowspan="1" colspan="1">(1.03&#x02013;1.19)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.17)</td><td valign="top" align="left" rowspan="1" colspan="1">0.218</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">(0.90&#x02013;1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.966</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.99&#x02013;1.13)</td><td valign="top" align="left" rowspan="1" colspan="1">0.089</td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB8</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">(0.95&#x02013;1.05)</td><td valign="top" align="left" rowspan="1" colspan="1">0.932</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA10</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.00</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.914</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA11</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.07</td><td valign="top" align="left" rowspan="1" colspan="1">(1.01&#x02013;1.14)</td><td valign="top" align="left" rowspan="1" colspan="1">0.032<xref ref-type="table-fn" rid="tfn4-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.07</td><td valign="top" align="left" rowspan="1" colspan="1">(1.00&#x02013;1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.833</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn3-ott-9-2317"><label>a</label><p>Multivariate Cox regression was adjusted for clinical factors (age, sex stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history).</p></fn><fn id="tfn4-ott-9-2317"><label>*</label><p>Indicates statistical significance.</p></fn><fn id="tfn5-ott-9-2317"><p><bold>Abbreviations:</bold> CI, confidence interval; NSCLC, non-small-cell lung cancer; TCGA, The Cancer Genome Atlas; HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ott-9-2317" position="float"><label>Table 3</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of integrin expression and overall survival for patients with adenocarcinoma and squamous cell carcinoma of lung cancer in TCGA cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Gene</th><th colspan="6" valign="top" align="left" rowspan="1">Adenocarcinoma (N=485)
<hr/></th><th colspan="6" valign="top" align="left" rowspan="1">Squamous cell carcinoma (N=474)
<hr/></th></tr><tr><th colspan="3" valign="top" align="left" rowspan="1">Univariate
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Multivariate<xref ref-type="table-fn" rid="tfn6-ott-9-2317">a</xref>
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Univariate
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Multivariate<xref ref-type="table-fn" rid="tfn6-ott-9-2317">a</xref>
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.138</td><td valign="top" align="left" rowspan="1" colspan="1">(0.967&#x02013;1.340)</td><td valign="top" align="left" rowspan="1" colspan="1">0.120</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.172</td><td valign="top" align="left" rowspan="1" colspan="1">(1.010&#x02013;1.360)</td><td valign="top" align="left" rowspan="1" colspan="1">0.037<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.032</td><td valign="top" align="left" rowspan="1" colspan="1">(0.755&#x02013;1.375)</td><td valign="top" align="left" rowspan="1" colspan="1">0.830</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.123</td><td valign="top" align="left" rowspan="1" colspan="1">(1.019&#x02013;1.238)</td><td valign="top" align="left" rowspan="1" colspan="1">0.019<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.044</td><td valign="top" align="left" rowspan="1" colspan="1">(0.901&#x02013;1.210)</td><td valign="top" align="left" rowspan="1" colspan="1">0.565</td><td valign="top" align="left" rowspan="1" colspan="1">0.983</td><td valign="top" align="left" rowspan="1" colspan="1">(0.870&#x02013;1.109)</td><td valign="top" align="left" rowspan="1" colspan="1">0.776</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA2B</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.920</td><td valign="top" align="left" rowspan="1" colspan="1">(0.836&#x02013;1.012)</td><td valign="top" align="left" rowspan="1" colspan="1">0.087</td><td valign="top" align="left" rowspan="1" colspan="1">0.961</td><td valign="top" align="left" rowspan="1" colspan="1">(0.855&#x02013;1.079)</td><td valign="top" align="left" rowspan="1" colspan="1">0.502</td><td valign="top" align="left" rowspan="1" colspan="1">0.973</td><td valign="top" align="left" rowspan="1" colspan="1">(0.879&#x02013;1.078)</td><td valign="top" align="left" rowspan="1" colspan="1">0.604</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.964</td><td valign="top" align="left" rowspan="1" colspan="1">(0.832&#x02013;1.117)</td><td valign="top" align="left" rowspan="1" colspan="1">0.623</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.160</td><td valign="top" align="left" rowspan="1" colspan="1">(1.043&#x02013;1.290)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.182</td><td valign="top" align="left" rowspan="1" colspan="1">(1.002&#x02013;1.394)</td><td valign="top" align="left" rowspan="1" colspan="1">0.047<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA4</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.904</td><td valign="top" align="left" rowspan="1" colspan="1">(0.777&#x02013;1.051)</td><td valign="top" align="left" rowspan="1" colspan="1">0.189</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.079</td><td valign="top" align="left" rowspan="1" colspan="1">(0.955&#x02013;1.218)</td><td valign="top" align="left" rowspan="1" colspan="1">0.221</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.316</td><td valign="top" align="left" rowspan="1" colspan="1">(1.135&#x02013;1.525)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.241</td><td valign="top" align="left" rowspan="1" colspan="1">(0.981&#x02013;1.570)</td><td valign="top" align="left" rowspan="1" colspan="1">0.072</td><td valign="top" align="left" rowspan="1" colspan="1">1.142</td><td valign="top" align="left" rowspan="1" colspan="1">(1.005&#x02013;1.299)</td><td valign="top" align="left" rowspan="1" colspan="1">0.042<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.053</td><td valign="top" align="left" rowspan="1" colspan="1">(0.855&#x02013;1.297)</td><td valign="top" align="left" rowspan="1" colspan="1">0.626</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.349</td><td valign="top" align="left" rowspan="1" colspan="1">(1.183&#x02013;1.537)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.208</td><td valign="top" align="left" rowspan="1" colspan="1">(1.014&#x02013;1.439)</td><td valign="top" align="left" rowspan="1" colspan="1">0.034<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.046</td><td valign="top" align="left" rowspan="1" colspan="1">(0.926&#x02013;1.183)</td><td valign="top" align="left" rowspan="1" colspan="1">0.470</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.899</td><td valign="top" align="left" rowspan="1" colspan="1">(0.781&#x02013;1.034)</td><td valign="top" align="left" rowspan="1" colspan="1">0.135</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.097</td><td valign="top" align="left" rowspan="1" colspan="1">(0.971&#x02013;1.240)</td><td valign="top" align="left" rowspan="1" colspan="1">0.136</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA8</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.950</td><td valign="top" align="left" rowspan="1" colspan="1">(0.880&#x02013;1.026)</td><td valign="top" align="left" rowspan="1" colspan="1">0.190</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.080</td><td valign="top" align="left" rowspan="1" colspan="1">(1.004&#x02013;1.161)</td><td valign="top" align="left" rowspan="1" colspan="1">0.040<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.052</td><td valign="top" align="left" rowspan="1" colspan="1">(0.937&#x02013;1.181)</td><td valign="top" align="left" rowspan="1" colspan="1">0.391</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA9</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.891</td><td valign="top" align="left" rowspan="1" colspan="1">(0.801&#x02013;0.990)</td><td valign="top" align="left" rowspan="1" colspan="1">0.032<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.934</td><td valign="top" align="left" rowspan="1" colspan="1">(0.820&#x02013;1.063)</td><td valign="top" align="left" rowspan="1" colspan="1">0.301</td><td valign="top" align="left" rowspan="1" colspan="1">1.102</td><td valign="top" align="left" rowspan="1" colspan="1">(1.004&#x02013;1.209)</td><td valign="top" align="left" rowspan="1" colspan="1">0.042<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.015</td><td valign="top" align="left" rowspan="1" colspan="1">(0.877&#x02013;1.173)</td><td valign="top" align="left" rowspan="1" colspan="1">0.846</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA10</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.023</td><td valign="top" align="left" rowspan="1" colspan="1">(0.913&#x02013;1.146)</td><td valign="top" align="left" rowspan="1" colspan="1">0.694</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.018</td><td valign="top" align="left" rowspan="1" colspan="1">(0.902&#x02013;1.150)</td><td valign="top" align="left" rowspan="1" colspan="1">0.768</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGA11</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.114</td><td valign="top" align="left" rowspan="1" colspan="1">(1.012&#x02013;1.227)</td><td valign="top" align="left" rowspan="1" colspan="1">0.028<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.060</td><td valign="top" align="left" rowspan="1" colspan="1">(0.926&#x02013;1.214)</td><td valign="top" align="left" rowspan="1" colspan="1">0.395</td><td valign="top" align="left" rowspan="1" colspan="1">1.046</td><td valign="top" align="left" rowspan="1" colspan="1">(0.967&#x02013;1.132)</td><td valign="top" align="left" rowspan="1" colspan="1">0.264</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAD</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.867</td><td valign="top" align="left" rowspan="1" colspan="1">(0.772&#x02013;0.974)</td><td valign="top" align="left" rowspan="1" colspan="1">0.016<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.999</td><td valign="top" align="left" rowspan="1" colspan="1">(0.906&#x02013;1.101)</td><td valign="top" align="left" rowspan="1" colspan="1">0.981</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAE</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.927</td><td valign="top" align="left" rowspan="1" colspan="1">(0.740&#x02013;1.160)</td><td valign="top" align="left" rowspan="1" colspan="1">0.507</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.996</td><td valign="top" align="left" rowspan="1" colspan="1">(0.803&#x02013;1.236)</td><td valign="top" align="left" rowspan="1" colspan="1">0.974</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAL</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.846</td><td valign="top" align="left" rowspan="1" colspan="1">(0.741&#x02013;0.965)</td><td valign="top" align="left" rowspan="1" colspan="1">0.013<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.836</td><td valign="top" align="left" rowspan="1" colspan="1">(0.638&#x02013;1.096)</td><td valign="top" align="left" rowspan="1" colspan="1">0.194</td><td valign="top" align="left" rowspan="1" colspan="1">1.043</td><td valign="top" align="left" rowspan="1" colspan="1">(0.945&#x02013;1.152)</td><td valign="top" align="left" rowspan="1" colspan="1">0.399</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAM</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.962</td><td valign="top" align="left" rowspan="1" colspan="1">(0.860&#x02013;1.075)</td><td valign="top" align="left" rowspan="1" colspan="1">0.491</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.130</td><td valign="top" align="left" rowspan="1" colspan="1">(1.020&#x02013;1.252)</td><td valign="top" align="left" rowspan="1" colspan="1">0.019<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.092</td><td valign="top" align="left" rowspan="1" colspan="1">(0.942&#x02013;1.266)</td><td valign="top" align="left" rowspan="1" colspan="1">0.241</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAV</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.235</td><td valign="top" align="left" rowspan="1" colspan="1">(1.027&#x02013;1.486)</td><td valign="top" align="left" rowspan="1" colspan="1">0.025<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.964</td><td valign="top" align="left" rowspan="1" colspan="1">(0.738&#x02013;1.259)</td><td valign="top" align="left" rowspan="1" colspan="1">0.788</td><td valign="top" align="left" rowspan="1" colspan="1">0.998</td><td valign="top" align="left" rowspan="1" colspan="1">(0.845&#x02013;1.177)</td><td valign="top" align="left" rowspan="1" colspan="1">0.978</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGAX</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.902</td><td valign="top" align="left" rowspan="1" colspan="1">(0.796&#x02013;1.022)</td><td valign="top" align="left" rowspan="1" colspan="1">0.106</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.097</td><td valign="top" align="left" rowspan="1" colspan="1">(0.974&#x02013;1.235)</td><td valign="top" align="left" rowspan="1" colspan="1">0.127</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.788</td><td valign="top" align="left" rowspan="1" colspan="1">(1.399&#x02013;2.286)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.191</td><td valign="top" align="left" rowspan="1" colspan="1">(0.822&#x02013;1.724)</td><td valign="top" align="left" rowspan="1" colspan="1">0.356</td><td valign="top" align="left" rowspan="1" colspan="1">1.231</td><td valign="top" align="left" rowspan="1" colspan="1">(1.006&#x02013;1.507)</td><td valign="top" align="left" rowspan="1" colspan="1">0.044<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.964</td><td valign="top" align="left" rowspan="1" colspan="1">(0.697&#x02013;1.333)</td><td valign="top" align="left" rowspan="1" colspan="1">0.824</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.105</td><td valign="top" align="left" rowspan="1" colspan="1">(0.807&#x02013;1.512)</td><td valign="top" align="left" rowspan="1" colspan="1">0.534</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.836</td><td valign="top" align="left" rowspan="1" colspan="1">(0.619&#x02013;1.131)</td><td valign="top" align="left" rowspan="1" colspan="1">0.245</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.834</td><td valign="top" align="left" rowspan="1" colspan="1">(0.659&#x02013;1.055)</td><td valign="top" align="left" rowspan="1" colspan="1">0.131</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.155</td><td valign="top" align="left" rowspan="1" colspan="1">(0.920&#x02013;1.450)</td><td valign="top" align="left" rowspan="1" colspan="1">0.216</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB1BP2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.985</td><td valign="top" align="left" rowspan="1" colspan="1">(0.841&#x02013;1.152)</td><td valign="top" align="left" rowspan="1" colspan="1">0.846</td><td valign="top" align="left" rowspan="1" colspan="1">0.981</td><td valign="top" align="left" rowspan="1" colspan="1">(0.843&#x02013;1.141)</td><td valign="top" align="left" rowspan="1" colspan="1">0.801</td><td valign="top" align="left" rowspan="1" colspan="1">0.978</td><td valign="top" align="left" rowspan="1" colspan="1">(0.855&#x02013;1.119)</td><td valign="top" align="left" rowspan="1" colspan="1">0.751</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB2</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.947</td><td valign="top" align="left" rowspan="1" colspan="1">(0.837&#x02013;1.072)</td><td valign="top" align="left" rowspan="1" colspan="1">0.392</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.089</td><td valign="top" align="left" rowspan="1" colspan="1">(0.969&#x02013;1.223)</td><td valign="top" align="left" rowspan="1" colspan="1">0.152</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB3</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.023</td><td valign="top" align="left" rowspan="1" colspan="1">(0.932&#x02013;1.121)</td><td valign="top" align="left" rowspan="1" colspan="1">0.636</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.081</td><td valign="top" align="left" rowspan="1" colspan="1">(0.986&#x02013;1.185)</td><td valign="top" align="left" rowspan="1" colspan="1">0.098</td><td valign="top" align="left" rowspan="1" colspan="1">0.890</td><td valign="top" align="left" rowspan="1" colspan="1">(0.747&#x02013;1.060)</td><td valign="top" align="left" rowspan="1" colspan="1">0.193</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB3BP</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.059</td><td valign="top" align="left" rowspan="1" colspan="1">(0.864&#x02013;1.297)</td><td valign="top" align="left" rowspan="1" colspan="1">0.583</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.828</td><td valign="top" align="left" rowspan="1" colspan="1">(0.658&#x02013;1.042)</td><td valign="top" align="left" rowspan="1" colspan="1">0.108</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB4</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.203</td><td valign="top" align="left" rowspan="1" colspan="1">(1.071&#x02013;1.352)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.029</td><td valign="top" align="left" rowspan="1" colspan="1">(0.905&#x02013;1.170)</td><td valign="top" align="left" rowspan="1" colspan="1">0.664</td><td valign="top" align="left" rowspan="1" colspan="1">1.042</td><td valign="top" align="left" rowspan="1" colspan="1">(0.927&#x02013;1.172)</td><td valign="top" align="left" rowspan="1" colspan="1">0.488</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.200</td><td valign="top" align="left" rowspan="1" colspan="1">(0.962&#x02013;1.498)</td><td valign="top" align="left" rowspan="1" colspan="1">0.106</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.063</td><td valign="top" align="left" rowspan="1" colspan="1">(0.899 &#x02013;1.256)</td><td valign="top" align="left" rowspan="1" colspan="1">0.474</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB6</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.002</td><td valign="top" align="left" rowspan="1" colspan="1">(0.883&#x02013;1.138)</td><td valign="top" align="left" rowspan="1" colspan="1">0.971</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.104</td><td valign="top" align="left" rowspan="1" colspan="1">(1.014&#x02013;1.202)</td><td valign="top" align="left" rowspan="1" colspan="1">0.022<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.019</td><td valign="top" align="left" rowspan="1" colspan="1">(0.917&#x02013;1.133)</td><td valign="top" align="left" rowspan="1" colspan="1">0.720</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB7</italic></td><td valign="top" align="left" rowspan="1" colspan="1">0.884</td><td valign="top" align="left" rowspan="1" colspan="1">(0.766&#x02013;1.021)</td><td valign="top" align="left" rowspan="1" colspan="1">0.094</td><td valign="top" align="left" rowspan="1" colspan="1">0.982</td><td valign="top" align="left" rowspan="1" colspan="1">(0.755&#x02013;1.278)</td><td valign="top" align="left" rowspan="1" colspan="1">0.894</td><td valign="top" align="left" rowspan="1" colspan="1">1.117</td><td valign="top" align="left" rowspan="1" colspan="1">(0.977&#x02013;1.278)</td><td valign="top" align="left" rowspan="1" colspan="1">0.105</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGB8</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.032</td><td valign="top" align="left" rowspan="1" colspan="1">(0.957&#x02013;1.114)</td><td valign="top" align="left" rowspan="1" colspan="1">0.412</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.903</td><td valign="top" align="left" rowspan="1" colspan="1">(0.816&#x02013;0.999)</td><td valign="top" align="left" rowspan="1" colspan="1">0.047<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.909</td><td valign="top" align="left" rowspan="1" colspan="1">(0.815&#x02013;1.013)</td><td valign="top" align="left" rowspan="1" colspan="1">0.083</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>ITGBL1</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1.018</td><td valign="top" align="left" rowspan="1" colspan="1">(0.904&#x02013;1.148)</td><td valign="top" align="left" rowspan="1" colspan="1">0.765</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1.090</td><td valign="top" align="left" rowspan="1" colspan="1">(1.000&#x02013;1.188)</td><td valign="top" align="left" rowspan="1" colspan="1">0.049<xref ref-type="table-fn" rid="tfn7-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.031</td><td valign="top" align="left" rowspan="1" colspan="1">(0.897&#x02013;1.185)</td><td valign="top" align="left" rowspan="1" colspan="1">0.670</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn6-ott-9-2317"><label>a</label><p>Multivariate Cox regression was adjusted for clinical factors (age, sex, stage, smoking history, neoadjuvant therapy history, and radiation therapy history).</p></fn><fn id="tfn7-ott-9-2317"><label>*</label><p>Indicates statistical significance.</p></fn><fn id="tfn8-ott-9-2317"><p><bold>Abbreviations:</bold> CI, confidence interval; TCGA, The Cancer Genome Atlas; HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ott-9-2317" position="float"><label>Table 4</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of integrin-related gene expression and overall survival for patients with NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Gene</th><th colspan="3" valign="top" align="left" rowspan="1">Univariate
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Multivariate<xref ref-type="table-fn" rid="tfn9-ott-9-2317">a</xref>
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">(95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">RAC1</td><td valign="top" align="left" rowspan="1" colspan="1">1.10</td><td valign="top" align="left" rowspan="1" colspan="1">(0.88&#x02013;1.36)</td><td valign="top" align="left" rowspan="1" colspan="1">0.395</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PLAUR</td><td valign="top" align="left" rowspan="1" colspan="1">1.16</td><td valign="top" align="left" rowspan="1" colspan="1">(1.05&#x02013;1.28)</td><td valign="top" align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.16</td><td valign="top" align="left" rowspan="1" colspan="1">(1.04&#x02013;1.30)</td><td valign="top" align="left" rowspan="1" colspan="1">0.010<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKACA</td><td valign="top" align="left" rowspan="1" colspan="1">0.77</td><td valign="top" align="left" rowspan="1" colspan="1">(0.60&#x02013;0.98)</td><td valign="top" align="left" rowspan="1" colspan="1">0.036<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.83</td><td valign="top" align="left" rowspan="1" colspan="1">(0.63&#x02013;1.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.196</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKAR1A</td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.86&#x02013;1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">0.591</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKAR1B</td><td valign="top" align="left" rowspan="1" colspan="1">1.08</td><td valign="top" align="left" rowspan="1" colspan="1">(0.94&#x02013;1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">0.254</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTK2</td><td valign="top" align="left" rowspan="1" colspan="1">1.10</td><td valign="top" align="left" rowspan="1" colspan="1">(0.89&#x02013;1.37)</td><td valign="top" align="left" rowspan="1" colspan="1">0.366</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ERBB2</td><td valign="top" align="left" rowspan="1" colspan="1">0.96</td><td valign="top" align="left" rowspan="1" colspan="1">(0.86&#x02013;1.07)</td><td valign="top" align="left" rowspan="1" colspan="1">0.465</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADAM15</td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1">(0.86&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.935</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMB2</td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.90&#x02013;1.14)</td><td valign="top" align="left" rowspan="1" colspan="1">0.855</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ABI1</td><td valign="top" align="left" rowspan="1" colspan="1">1.02</td><td valign="top" align="left" rowspan="1" colspan="1">(0.83&#x02013;1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">0.886</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTPRA</td><td valign="top" align="left" rowspan="1" colspan="1">1.12</td><td valign="top" align="left" rowspan="1" colspan="1">(0.89&#x02013;1.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.324</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ARHGAP5</td><td valign="top" align="left" rowspan="1" colspan="1">0.93</td><td valign="top" align="left" rowspan="1" colspan="1">(0.77&#x02013;1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">0.437</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EPS8</td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">(0.90&#x02013;1.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.707</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRKCA</td><td valign="top" align="left" rowspan="1" colspan="1">1.06</td><td valign="top" align="left" rowspan="1" colspan="1">(0.96&#x02013;1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">0.241</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ILK</td><td valign="top" align="left" rowspan="1" colspan="1">1.22</td><td valign="top" align="left" rowspan="1" colspan="1">(1.00&#x02013;1.47)</td><td valign="top" align="left" rowspan="1" colspan="1">0.046<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.27</td><td valign="top" align="left" rowspan="1" colspan="1">(1.00&#x02013;1.60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.049<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SRC</td><td valign="top" align="left" rowspan="1" colspan="1">1.11</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.246</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD81</td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.84&#x02013;1.21)</td><td valign="top" align="left" rowspan="1" colspan="1">0.903</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">YWHAZ</td><td valign="top" align="left" rowspan="1" colspan="1">1.32</td><td valign="top" align="left" rowspan="1" colspan="1">(1.10&#x02013;1.59)</td><td valign="top" align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.20</td><td valign="top" align="left" rowspan="1" colspan="1">(0.96&#x02013;1.51)</td><td valign="top" align="left" rowspan="1" colspan="1">0.113</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IGF1R</td><td valign="top" align="left" rowspan="1" colspan="1">1.07</td><td valign="top" align="left" rowspan="1" colspan="1">(0.97&#x02013;1.18)</td><td valign="top" align="left" rowspan="1" colspan="1">0.186</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SPP1</td><td valign="top" align="left" rowspan="1" colspan="1">1.09</td><td valign="top" align="left" rowspan="1" colspan="1">(1.04&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.08</td><td valign="top" align="left" rowspan="1" colspan="1">(1.02&#x02013;1.15)</td><td valign="top" align="left" rowspan="1" colspan="1">0.012<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PXN</td><td valign="top" align="left" rowspan="1" colspan="1">1.31</td><td valign="top" align="left" rowspan="1" colspan="1">(1.13&#x02013;1.51)</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.25</td><td valign="top" align="left" rowspan="1" colspan="1">(1.06&#x02013;1.48)</td><td valign="top" align="left" rowspan="1" colspan="1">0.009<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTK2B</td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td><td valign="top" align="left" rowspan="1" colspan="1">(0.82&#x02013;1.05)</td><td valign="top" align="left" rowspan="1" colspan="1">0.212</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMC1</td><td valign="top" align="left" rowspan="1" colspan="1">1.19</td><td valign="top" align="left" rowspan="1" colspan="1">(1.03&#x02013;1.37)</td><td valign="top" align="left" rowspan="1" colspan="1">0.020<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.12</td><td valign="top" align="left" rowspan="1" colspan="1">(0.94&#x02013;1.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.197</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VLDLR</td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">(0.90&#x02013;1.07)</td><td valign="top" align="left" rowspan="1" colspan="1">0.662</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RPS6KB1</td><td valign="top" align="left" rowspan="1" colspan="1">1.04</td><td valign="top" align="left" rowspan="1" colspan="1">(0.82&#x02013;1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">0.767</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDC2</td><td valign="top" align="left" rowspan="1" colspan="1">1.02</td><td valign="top" align="left" rowspan="1" colspan="1">(0.94&#x02013;1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">0.628</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDC4</td><td valign="top" align="left" rowspan="1" colspan="1">1.04</td><td valign="top" align="left" rowspan="1" colspan="1">(0.93&#x02013;1.16)</td><td valign="top" align="left" rowspan="1" colspan="1">0.506</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLN1</td><td valign="top" align="left" rowspan="1" colspan="1">1.15</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.35)</td><td valign="top" align="left" rowspan="1" colspan="1">0.079<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.19</td><td valign="top" align="left" rowspan="1" colspan="1">(0.99&#x02013;1.44)</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VEGFA</td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1">(0.89&#x02013;1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">0.929</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EGFR</td><td valign="top" align="left" rowspan="1" colspan="1">1.05</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.12)</td><td valign="top" align="left" rowspan="1" colspan="1">0.134</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD9</td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td><td valign="top" align="left" rowspan="1" colspan="1">(0.84&#x02013;1.00)</td><td valign="top" align="left" rowspan="1" colspan="1">0.055<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.83</td><td valign="top" align="left" rowspan="1" colspan="1">(0.74&#x02013;0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="tfn10-ott-9-2317">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL18A1</td><td valign="top" align="left" rowspan="1" colspan="1">1.08</td><td valign="top" align="left" rowspan="1" colspan="1">(0.98&#x02013;1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">0.137</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GIPC1</td><td valign="top" align="left" rowspan="1" colspan="1">1.01</td><td valign="top" align="left" rowspan="1" colspan="1">(0.86&#x02013;1.17)</td><td valign="top" align="left" rowspan="1" colspan="1">0.925</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn9-ott-9-2317"><label>a</label><p>Multivariate Cox regression was adjusted for clinical factors (age, sex, stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history).</p></fn><fn id="tfn10-ott-9-2317"><label>*</label><p>Indicates statistical significance.</p></fn><fn id="tfn11-ott-9-2317"><p><bold>Abbreviations:</bold> CI, confidence interval; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap></floats-group></article>